294181-97-8

Usage

Ethyl ester derivative

The compound is an ethyl ester derivative of 2,2-difluoro-2-(quinolin-2-yl)acetic acid, meaning it has an ethoxy group attached to the parent compound.

α7 nicotinic acetylcholine receptor agonist

The compound is a selective agonist of the α7 nicotinic acetylcholine receptor, which means it binds to and activates this specific receptor in the nervous system.

Potential therapeutic applications

The compound has potential therapeutic applications, particularly in the treatment of neurodegenerative diseases such as Alzheimer's and schizophrenia.

Ongoing research and clinical trials

The unique structure and pharmacological properties of the compound make it a promising candidate for drug development, and it is currently being studied in ongoing research and clinical trials.

Upstream product

• 2005-43-8 2-bromoquinoline 
• 667-27-6 Ethyl bromodifluoroacetate 
• 6560-83-4 2-iodoquinoline 
• 1308915-11-8 ethyl 2,2-difluoro-2-(triethylsilyl)acetate 
• 205865-67-4 α-(trimethylsilyl)difluoroacetic acid ethyl ester 

Downstream Products

• 294182-08-4 2,2-difluoro-1-(2,4-difluorophenyl)-2-(2-quinolinyl)ethanone 
• 1075184-01-8 2-(difluoromethyl)quinoline 
• 294182-29-9 2-[difluoro[2-(2,4-difluorophenyl)-2-oxiranyl]methyl]quinoline 

Relevant academic research and scientific papers

Manufacturing method of making heteroarylacetic compd. defluoromethyl

PROBLEM TO BE SOLVED: To provide a method for easily producing a difluoromethyl heteroaryl compound with high yield at low cost. SOLUTION: In the method for producing the difluoro methyl heteroaryl compound, a halogenated heteroaryl compound and a α-silyldifluoro acetate ester compound are reacted with each other in the presence of a metal halogenated compound. COPYRIGHT: (C)2012,JPOandINPIT

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to compounds of the formula (I), the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

A new method for aromatic difluoromethylation: Copper-catalyzed cross-coupling and decarboxylation sequence from aryl iodides

A new methodology for aromatic difluoromethylation is described. Aryl iodides reacted with α-silyldifluoroacetates upon treatment with copper catalyst in DMSO or DME to give the corresponding aryldifluoroacetates in moderate to good yields. The subsequent hydrolysis of aryldifluoroacetates and KF-promoted decarboxylation afforded a variety of difluoromethyl aromatics.

New antifungal 1,2,4-triazoles with difluoro(heteroaryl)methyl moiety

New 1,2,4-triazoles (1) having a difluoro(heteroaryl)methyl moiety were designed and synthesized via 1-aryl-2,2-difluoro-2- (heteroaryl)ethanones (2), which were prepared by two routes starting from the reaction of ethyl 2,2- difluoro(heteroaryl)acetate with phenyllithiums (Route A) and from the reaction of chlorodifluoro(heteroaryl)methane with benzaldehydes (Route B). The compounds 1 except for 1g show antifungal activities against yeasts and filamentous fungi in vitro, especially (+)-If have equal or superior activities compared to those of itraconazole.